Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Nina V Chaika"'
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0176820 (2017)
BACKGROUND:Mucin1 (MUC1), a glycoprotein associated with chemoresistance and an aggressive cancer phenotype, is aberrantly overexpressed in triple-negative breast cancer (TNBC). Recent studies suggest that MUC1 plays a role in modulating cancer cell
Externí odkaz:
https://doaj.org/article/8e6bfd10895c4376a889c7177b58ea9e
Publikováno v:
PLoS ONE, Vol 12, Iss 6, p e0179098 (2017)
[This corrects the article DOI: 10.1371/journal.pone.0176820.].
Externí odkaz:
https://doaj.org/article/b7bc56ba9a444cf68c11b7b37e3229c3
Autor:
Nina V Chaika, Fang Yu, Vinee Purohit, Kamiya Mehla, Audrey J Lazenby, Dominick DiMaio, Judy M Anderson, Jen Jen Yeh, Keith R Johnson, Michael A Hollingsworth, Pankaj K Singh
Publikováno v:
PLoS ONE, Vol 7, Iss 3, p e32996 (2012)
Pancreatic cancer is the fourth leading cause of cancer related deaths in the United States with a five-year survival rate of 6%. It is characterized by extremely aggressive tumor growth rate and high incidence of metastasis. One of the most common a
Externí odkaz:
https://doaj.org/article/3d07d5aecc804eda98e4f8aa643653bf
Autor:
Ryan J. King, Surendra K. Shukla, Chunbo He, Enza Vernucci, Ravi Thakur, Kuldeep S. Attri, Aneesha Dasgupta, Nina V. Chaika, Scott E. Mulder, Jaime Abrego, Divya Murthy, Venugopal Gunda, Camila G. Pacheco, Paul M. Grandgenett, Audrey J. Lazenby, Michael A. Hollingsworth, Fang Yu, Kamiya Mehla, Pankaj K. Singh
Publikováno v:
Oncogene. 41:971-982
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae0dce488cdfbc65b01dce4e49232e21
https://doi.org/10.1038/s41388-021-02132-6
https://doi.org/10.1038/s41388-021-02132-6
Autor:
Pankaj K. Singh, Chi Lin, Tadayoshi Bessho, Fang Yu, Shuo Wang, Sicong Li, Ryan J. King, Nina V. Chaika, Aneesha Dasgupta, Enza Vernucci, Gennifer D. Goode, Surendra K. Shukla, Jaime Abrego, Joshua Souchek, Venugopal Gunda
Figure S1. BrPA inhibits MUC1-mediated nucleotide metabolism. Figure S2. Immunohistochemical staining for MUC1 in tumor sections.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2244741d34c5642c77c072e2e5d68916
https://doi.org/10.1158/1078-0432.22467183.v1
https://doi.org/10.1158/1078-0432.22467183.v1
Data from MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer
Autor:
Pankaj K. Singh, Chi Lin, Tadayoshi Bessho, Fang Yu, Shuo Wang, Sicong Li, Ryan J. King, Nina V. Chaika, Aneesha Dasgupta, Enza Vernucci, Gennifer D. Goode, Surendra K. Shukla, Jaime Abrego, Joshua Souchek, Venugopal Gunda
Purpose: MUC1, an oncogene overexpressed in multiple solid tumors, including pancreatic cancer, reduces overall survival and imparts resistance to radiation and chemotherapies. We previously identified that MUC1 facilitates growth-promoting metabolic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07a38913aee94df543f33836c0388a54
https://doi.org/10.1158/1078-0432.c.6526560.v1
https://doi.org/10.1158/1078-0432.c.6526560.v1
Autor:
Pankaj K. Singh, Aaron R. Sasson, Jean Grem, Lyudmyla Berim, Audrey J. Lazenby, Fang Yu, Nina V. Chaika, Jaime Abrego, Enza Vernucci, Venugopal Gunda, Ryan J. King, Surendra K. Shukla, Saber Tadros
Figure S1: FASN inhibition with orlistat shows synergistic activity with gemcitabine in AsPC-1 cells; Figure S2: Effect of orlistat on the lipid content of pancreatic cancer cells; Figure S3: Platensimycin shows synergistic activity with gemcitabine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::596cf661396a3ee8aaf765d72fe2857b
https://doi.org/10.1158/0008-5472.22414755
https://doi.org/10.1158/0008-5472.22414755
Autor:
Pankaj K. Singh, Aaron R. Sasson, Jean Grem, Lyudmyla Berim, Audrey J. Lazenby, Fang Yu, Nina V. Chaika, Jaime Abrego, Enza Vernucci, Venugopal Gunda, Ryan J. King, Surendra K. Shukla, Saber Tadros
Pancreatic adenocarcinoma is moderately responsive to gemcitabine-based chemotherapy, the most widely used single-agent therapy for pancreatic cancer. Although the prognosis in pancreatic cancer remains grim in part due to poor response to therapy, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01df4e3ea24249e070fa6c7886c161f4
https://doi.org/10.1158/0008-5472.c.6509073.v1
https://doi.org/10.1158/0008-5472.c.6509073.v1
Autor:
Clemens Steegborn, Chunbo He, Fang Yu, Antonello Mai, Kuldeep S. Attri, Sarika Chaudhary, Eric Verdin, Ping Lan, Tuo Hu, Sergio Valente, Surendra K. Shukla, Audrey J. Lazenby, Enza Vernucci, Ravi Thakur, David A. Tuveson, Divya Murthy, Xiao Fu, Nicholas J Mullen, Dante Rotili, Ryan J. King, Pankaj Singh, Dezhen Wang, Kamiya Mehla, Marco Tafani, Scott E. Mulder, Robin High, Kanupriya Jha, Johan Auwerx, Nina V. Chaika, Kasturi Siddhanta, Camila G. Pacheco
Publikováno v:
Gastroenterology
BACKGROUND & AIMS: SIRT5 plays pleiotropic roles via post-translational modifications, serving as a tumor suppressor, or an oncogene, in different tumors. However, the role SIRT5 plays in the initiation and progression of pancreatic ductal adenocarci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::467d75d337ef5dbb97182174d32e9b77
https://doi.org/10.1053/j.gastro.2021.06.045
https://doi.org/10.1053/j.gastro.2021.06.045
Autor:
Nicholas J. Mullen, Ravi Thakur, Surendra K. Shukla, Nina V. Chaika, Sai Sundeep Kollala, Dezhen Wang, Chunbo He, Yuki Fujii, Shikhar Sharma, Scott E. Mulder, David B. Sykes, Pankaj K. Singh
Publikováno v:
Cancer Lett
Inhibitors of dihydroorotate dehydrogenase (DHODH), a key enzyme for de novo synthesis of pyrimidine nucleotides, have failed in clinical trials for various cancers despite robust efficacy in preclinical animal models. To probe for druggable mediator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7de3aeb07860a3c6c3320ebfc6d73474
https://europepmc.org/articles/PMC10305837/
https://europepmc.org/articles/PMC10305837/